Sucampo Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones and other novel drug technologies in the Americas, Europe, and Asia. It develops prostones to treat gastrointestinal, ophthalmologic, central nervous system, vascular, and respiratory diseases, as well as for other therapeutic applications. The company offers AMITIZA for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women; and RESCULA for the treatment of open-angle glaucoma and ocular hypertension. The company’s products in pipeline include Amitiza, which has completed Phase III clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) or opioid-induced constipation in patients with chronic non-cancer pain; in Phase 3 clinical trial for the treatment of OBD in cancer patients; in a clinical study for pediatric constipation; and in preclinical stage for inflammatory bowel disease (IBD). Its products in pipeline also comprise RESCULA that is in Phase IIb clinical trial for the treatment of dry age-related macular degeneration; and has orphan drug status for retinitis pigmentosa. In addition, the company is developing Cobiprostone, which has completed Phase II clinical trial for the prevention of non-steroidal anti-inflammatory drug induced ulcers; has completed Phase II clinical trial for treating cystic fibrosis; is in formulation development for the treatment of oral mucositis; and is in preclinical stage for the treatment of IBD, wound healing, and chronic obstructive pulmonary disease. Further, it is developing SPI-3608 that is in preclinical stage for the treatment of spinal stenosis; and SPI-017, which has completed Phase I clinical trial for the treatment of peripheral arterial disease and spinal stenosis. Sucampo Pharmaceuticals, Inc. is headquartered in Bethesda, Maryland.